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Abstract Bladder cancer is the second commonest urinary
tract malignancy with 70–80 % being non-muscle invasive
(NMIBC) at diagnosis. Patients with high-risk NMIBC (T1/
Tis, with high grade/G3, or CIS) represent a challenging group
as they are at greater risk of recurrence and progression.
Intravesical Bacilli Calmette-Guerin (BCG) is commonly
used as first line therapy in this patient group but there is a
current worldwide shortage. BCG has been shown to reduce
recurrence in high-risk NMIBC and is more effective that
other intravesical agents including mitomycin C, epirubicin,
interferon-alpha and gemcitabine. Primary cystectomy offers
a high change of cure in this cohort (80–90 %) and is a more
radical treatment option which patients need to be counselled
carefully about. Bladder thermotherapy and electromotive
drug administration with mitomycin C are alternative thera-
pies with promising short-term results although long-term fol-
low-up data are lacking.
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Introduction
Bladder cancer is the second frequent urinary tract malignancy
and out of all malignancies worldwide ranks as the 7th
commonest male and 17th commonest female cancer [1].
The most common symptom at presentation is haematuria
and diagnosis is usually made following transurethral resection
(TUR). At diagnosis, 70–80% of bladder cancer is non-muscle
invasive (NMIBC) and of those 20–25 % progress to muscle-
invasive disease during a patient’s lifetime [2]. Pathologically,
NMIBC papillary tumours confined to the epithelium and
those which have invaded the underlying lamina propria are
classified as stage Ta and stage T1, respectively, while flat, high
grade tumours that are confined to the mucosa are classified as
carcinoma in situ (CIS/Tis) [3]. Following TUR and patholog-
ical analysis, NMIBC can be risk stratified into low, interme-
diate and high-risk groups depending on the probability of
recurrence and progression to muscle-invasive disease [4].
Patients with high-risk NMIBC (T1, with high grade/G3,
and/ or CIS) represent a challenging group with an increased
5-year risk of recurrence (up to 80 %) and progression (up to
50 %) according to the EORTC risk stratification tables [5].
Treatment options for high-risk NMIBC include intravesical
immunotherapy with Bacillus Calmette-Guerin (BCG), other
intravesical chemotherapy (with agents such as mitomycin C or
epirubicin) or primary radical cystectomy. Intravesical BCG has
been proven to reduce and delay tumour progression to muscle-
invasive disease and has been first line therapy for many patients
with high-risk NMIBC [6]. The response to intravesical treat-
ment with BCG or chemotherapy is also an important prognostic
factor for subsequent progression and death caused by bladder
cancer [7–9]. Approximately 10–20 % of complete responders
eventually progress to muscle-invasive disease, compared with
66 % of non-responders [10, 11]. There is a current worldwide
shortage of intravesical BCG due to problems in manufacturing
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and limited supplies are available in centres [12]. Therefore, in
this current climate, other treatment options for patients with
high-risk NMIBC need to be considered.
This paper reviews the current evidence for intravesical
BCG and alternative therapies for this challenging group of
patients with high-risk non-muscle-invasive bladder cancer.
Intravesical Immunotherapy with BCG
BCG is a live attenuated strain ofMycobacterium bovis, orig-
inally developed as a vaccine for tuberculosis. There are sev-
eral strains available from different manufacturers with the
commonest used in the UK being Oncotice BCG®. The con-
tent of a vial is reconstituted with 50 ml of saline and then
administered through a urethral catheter to remain in the uri-
nary bladder for about 2 h’ time. The mechanism of action is
incompletely understood but it is postulated to work via a
local immune response characterised by induced expression
of cytokines in the urine and bladder wall [13]. Before starting
BCG in new patients, it is important to adequately debulk all
visible tumour and re-resect T1 high grade tumours to reduce
understaging. BCG strain may have an impact on treatment
outcome in NMIBC immunotherapy. A recent prospective
randomised study of 142 high-risk NMIBC patients with
two of the commonest BCG strains (Connaught and Tice)
showed that treatment with BCG Connaught conferred signif-
icantly greater 5-year recurrence-free survival compared with
treatment with BCG Tice [14].
Level 1 evidence from meta-analyses by Shelley et al.
(2001) and Han et al. (2006) have confirmed the that BCG
after TUR is superior to TUR alone or TUR and intravesical
chemotherapy for the prevention of recurrence of NMIBC in
patients with Ta and T1 tumours [15, 16]. Two other meta-
analyses have demonstrated that BCG therapy prevents, or at
least delays, the risk of tumour progression in patients at in-
termediate and high risk of tumour recurrence [17, 18]. As
such, the landmark EORTC-GUCG analysis of over 4800
subjects from 24 RCTs comparing BCG (with maintenance)
to other therapies (TUR alone, TUR with intravesical chemo-
therapy and TURB with other immunotherapy) showed a re-
duction of 27 % in the odds of progression with BCG main-
tenance treatment [18]. Particularly in the high-risk NMIBC
group, studies have confirmed the superiority of BCG for
prevention of tumour recurrence over intravesical mitomycin
C alone, intravesical epirubicin alone or a combination of
epirubicin and interferon [18–20]. These data therefore sug-
gest that in patients with NMIBC at high risk of recurrence,
BCGwith at least 1 year of maintenance is more effective than
chemotherapy for prevention of recurrence. Although BCG is
a very effective treatment, there is a consensus that not all
patients with NMIBC should be treated with BCG due to the
risk of toxicity [21, 22]. Whilst the induction BCG
instillations are classically given according to the empirical
6-weekly induction schedule that was introduced by
Morales, the BCG maintenance schedule has not been
standardised [23]. One common maintenance BCG sched-
ule used in clinical trials would consist of three weekly
instillations at months 3, 6 and 12 following induction
treatment [6, 17].
With limited supplies of intravesical BCG available, judi-
cious use of the dwindling reserves must be made. For patient
already on treatment, BCG maintenance can be stopped after
1 year in patients without CIS and continued for up to 3 years
in patients with CIS at a reduced (1/3) dose (Table 1, option 1).
This schedule does not seem to lead to more tumour progres-
sion, although a higher risk of recurrence has been reported in
the patients with very high risk [31].
Another option for new patients would be using a reduced
dose of 1/3 BCG for induction and maintenance for 1 year
(Table 1, option 2). This schedule has been investigated by the
an EORTC-GU trial and could not show a difference in the
number of patients progressing as compared to full dose rate
[31]. Alternatively, some expert recommendation suggest full
dose BCG to be given as a 6-week induction course followed by
maintenance at 1/3 dose [12]. However, if there is no or limited
BCG available, primary cystectomy should be offered to all
surgically fit patients with high-risk NMIBC as the most effec-
tive option compared with other non BCG-based treatments.
Should patients have a recurrence of their high-risk NMIBC
under BCG treatment, expert judgement advises no further chal-
lenge with BCG should be offered but radical cystectomy or
device-assisted therapy should be considered [12].
Intravesical Mitomycin
Mitomycin C with maintenance has been shown to reduce the
risk of recurrence in intermediate and high-risk NMIBC, but it
is not as effective as BCG. Trials of intravesical mitomycin C
versus BCG can be difficult to interpret due to heterogeneous
treatment groups and variable intervention schedules. Three
main RCTs have dealt specifically with patients at high risk of
recurrence [32–34]. Those include patients with recurrent Ta/
T1 tumours, T1G3 tumours or concomitant CIS.
Rintala et al. reported an RCT of 109 patients with recur-
rent Ta/T1G1-3 tumours or CIS treated (using weekly instal-
lation of BCG for 4 weeks followed by two monthly instilla-
tions up to 1 year) and found a complete response to BCG
(defined as lack of recurrence) in 97 % (vs 70 % for mainte-
nance mitomycin using same similar schedule) at 2-year fol-
low-up [33]. In another RCT of 469 patients from the SWOG
group (patients at high risk due to having had two occurrences
of tumour within 56 weeks, stage T1 tumour or three or more
tumours within 16 weeks, or concurrent CIS), recurrence-free
survival was significantly longer with BCG but there was no
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difference in progression [34]. In another study by Malstorm
et al., 126 patients with multiple or recurrent Ta/T1G1-2 or
CIS or T1G3 were randomised to BCG with maintenance or
mitomycin C [24]. The authors reported a significant differ-
ence in disease-free rates at 5 years (47 % for BCG arm vs
34 % for mitomycin) but no difference in progression rates.
In an individual patient data meta-analysis (over 2800 pa-
tients) of nine randomised studies comparing long-term out-
comes of intravesical therapies in NMIBC, the trials with
BCG maintenance showed a 32 % reduction in risk of recur-
rence on BCG compared tomitomycin while there was a 28%
risk increase for BCG in the trials without maintenance. There
was however no statistically significant differences regarding
progression, overall survival and cancer-specific survival be-
tween the two treatments [25]. These data show that
intravesical BCGwith maintenance has superior activity com-
pared to mitomycin C (MMC) for the prophylaxis of tumour
recurrence in high-risk patients. However, it is worth noting
that in the RCTs, there was a response rate associated with use
of maintenance mitomycin C as regards the reduction in re-
currence rates even in high-risk patients. For this reason whilst
accepting a higher risk of recurrence, an induction course of
MMC followed by maintenance seems to be a viable alterna-
tive to BCG in times of shortage, especially for high-risk
NMIBC patients without features putting them at the highest
risk (pT1G3 with CIS for example) (Table 1, option 3). Due to
the current lack of evidence as to which schedule is the most
efficient, we currently deliver a 6-week induction course
followed by weekly maintenance for 1 year with cystoscopic
assessment at 3 months.
Intravesical Chemotherapy with Hyperthermia
Thermal energy appears to improve the absorption of several
intravesical agents, and as such adjunctive hyperthermia has
been shown to increase cytotoxicity in bladder cells in in vitro
and animal models [35–37]. Several devices are available to
deliver thermochemotherapy for NMIBCwith the commonest
used heat delivery system being Synergo® (Medical
Enterprises Europe B.V., Amsterdam, Netherlands). This ma-
chine delivers local hyperthermia in conjunction with
intravesical chemotherapy using a 915-MHz intravesical ra-
diofrequency energy applicator placed on a thermocouple-
controlled 20 F urethral catheter [12]. Other HT systems
include the BSD-2000 (currently used for high-risk bladder
cancer part of a quadrimodal treatment plan involving TUR,
radiation therapy, chemotherapy and hyperthermia), the
ALBA hyperthermia system (which includes a 3D system),
the BWT system by Elmedical, the Sonotherm 1000 and the
Combat BRS system [38–40].
A recent systemic review and meta-analysis of 22 trials ex-
amining intravesical chemohyperthermia (CHT) for NMIBC
showed a 59 % reduction in recurrence rate for TURB +
CHT compared to TURBT + chemotherapy alone [41].
However, due to short follow-up, no conclusions could be
drawn about time to recurrence and progression. In addition,
the overall bladder preservation rate after CHTwas 87.6 %.
In one of the few studies with long-term follow-up,
Colombo et al. reported on a cohort of 83 patients with
intermediate/high grade NMIBC (randomised to undergoing
thermotherapy with Synergo vs standard mitomycin C) with a
median follow-up of 91 months [42]. They showed a signifi-
cantly better 10-year disease-free survival rate for
thermochemotherapy (53 vs 15 % for mitomycin only).
Bladder preservation rates for thermochemotherapy were also
significantly higher (86 vs 79 %).
The European Synergo working party recently reported
outcomes of CHT with mitomycin C in CIS patients. In this
multicentre study of 51 patients with primary or BCG-failing
CIS, the authors reported an initial complete response rate of
92 %, which remained approximately 50 % after 2 years [43].
O v e r a l l , t h e e a r l y e v i d e n c e s u g g e s t s t h a t
chemohyperthermia offers an additional benefit to current clin-
ical management methods, as an alternative treatment should
BCG not be available, especially for higher risk NMIBC pa-
tients with T1 tumours or CIS for whom upfront radical
cystectomy is not an option (Table 1, option 4). More studies
are needed to further examine long-term oncological outcomes,
treatment complications and limitations of this approach.
Electromotive Intravesical Drug Administration
Electromotive drug administration (EMDA) uses an electric
current to enhance transepithelial drug penetration [44].
EMDA is administered via a battery-powered generator deliv-
ering an electric current of 0–30 mA DC at 0–55 V, which is
passed between two electrodes. An active electrode is placed
into the bladder as part of a transurethral catheter and
Table 1 Options in BCG
shortage Option 1 [19] Full dose BCG with maintenance only for 1 year (if CIS continue for 2–3 years)
Option 2 [19] One third dose BCG for induction and maintenance for 1 year
Option 3 [6, 21] Induction and maintenance course of mitomycin C
Option 4 [24, 25] Intravesical chemotherapy agents with thermotherapy
Option 5 [26, 27] Induction and maintenance course of gemcitabine
Option 6 [28–30] Primary radical cystectomy
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dispersive ground electrode pads are placed on the skin of the
lower abdomen [26].
The penetration of MMC into the bladder wall with EMDA
is significantly greater (by four to seven times) than that
achieved by passive diffusion as shown in in vitro studies [27,
45]. In clinical practice, EMDA MMC has been shown to be
safe with no life-threatening adverse events. Most reports on
EMDA have focussed on its role following first TURBT and
there are limited reports of its use in high-risk patients.
In one such study, Di Stasi et al. reported a prospective
RCT of 108 patients (with multifocal Tis, including 98 with
T1 tumours) who were randomised into three equal groups of
36 each who underwent 40 mg electromotive MMC instilla-
tion with 20 mA electric current for 30 min, 40 mg passive
MMCwith a dwell time of 60min or 81mg BCGwith a dwell
time of 120 min. The complete response for electromotive
versus passive MMC at 3 and 6 months was 53 versus 28 %
(p = 0.036) and 58 versus 31 % (p = 0.012). For BCG, the
responses were 56 and 64 %. Median time to recurrence was
35 versus 19.5 months (p = 0.013) and for BCG it was
26 months [28].
In another RCTof 212 patients comparing sequential BCG
and electromotive mitomycin C versus BCG alone for high-
risk superficial bladder cancer, patients assigned sequential
BCG and electromotive mitomycin had higher disease-free
interval than did those assigned BCG alone (69 vs 21 months)
[29]. Patients assigned sequential BCG and electromotive mi-
tomycin also had lower recurrence (41.9 vs 57.9 %), progres-
sion (9.3 vs 21.9 %), overall mortality (21.5 vs 32.4 %) and
disease-specific mortality (5.6 vs 16.2 %).
These data suggest that intravesical electromotive adminis-
tration appears to increase bladder uptake of MMC, resulting
in an improved response rate in cases of high-risk NMIBC.
This appears equivalent to BCG in the short term but long-
term efficacy data are lacking. Therefore, it is currently not
possible to give a conclusive recommendation about the place
for this modality in times of BCG shortage.
Other Intravesical Agents
Doxorubicin
Doxorubicin is an anthracycline used in superficial bladder
cancer. RCTs comparing it to BCG have shown that BCG is
superior in preventing or delaying tumour recurrence both in
papillary Ta and T1 cancers and CIS [30, 46, 47].
Intravesical Gemcitabine
A Cochrane review on the efficacy of gemcitabine
showed six trials with over 700 patients [48]. Three trials
compared gemcitabine with intravesical BCG but a meta-
analysis was not possible due to clinical heterogeneity.
In untreated patients at intermediate risk of recurrence
(primary Ta-T1 no CIS), one trial showed that
gemcitabine and BCG were similar with respective re-
currence rates of 25 and 30 % and overall progression
equal. In a second trial of high-risk patients, the recur-
rence rate was significantly greater with gemcitabine
compared to BCG (53.1 and 28.1 %) and the time to
recurrence significantly shorter with gemcitabine (25.5
vs 39.4 months). Finally in a third trial of high-risk
patients who had failed previous intravesical BCG ther-
apy, gemcitabine was associated with significantly fewer
recurrences (52.5 vs 87.5 %) and a longer time to recur-
rence (3 .9 vs 3.1 months) compared to BCG.
Progression rates were similar in both groups (33 vs
37.5 %) with no significant differences in grade 2 or 3
toxicities. In summary, compared to intravesical BCG
therapy, gemcitabine had similar effects in intermediate
risk patients but was less effective in high-risk patient
and remains frequently reserved for BCG refractory pa-
tients. A proposed schedule for example is induction
with intravesical gemcitabine (1–2 g in 50 cc of sterile
water over 90 min) followed by a monthly maintenance
(Table 1, option 5) [49].
Radical Cystectomy
Radical cystectomy has been considered the gold standard
treatment for patients with high-risk NMIBC, such as
multiple and/or large T1G3 with CIS or recurrent high-
risk NMIBC after intravesical full dose BCG for 1–3 years
[21, 50].
The high risk of recurrence and progression associated
with conservative treatment of high-risk NMIBC indicates
there is a considerable risk of understaging by TUR and
imaging alone [51]. Cystectomy allows pelvic lymphade-
nectomy which permits accurate staging (up to 18 % of
T1 patients have positive lymph nodes) and can be thera-
peutic regarding nodal metastases [52]. Herr and Sogani
reported on 307 high-risk bladder cancer patients of
whom 90 underwent cystectomy for relapse. Cancer-
specific survival (CSS) was greatest in those undergoing
cystectomy <2 years after BCG initiation compared to
those whose cystectomy was performed >2 years after
BCG induction [53]. Lambert et al. also noted poorer
recurrence-free survival (RFS) and CSS in a cohort of
patients undergoing cystectomy for T1G3 carcinoma after
1998 versus those treated with cystectomy before 1998.
They postulated that the decrease in survival was the re-
sult of higher and perhaps inappropriately prolonged use
of intravesical therapy in the modern era [54]. The above
data highlights the danger of delaying cystectomy in pa-
tients with highest-risk NMIBC and the need to risk-
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stratify all such T1 patients. The ability to identify candi-
dates at high risk for progression is indispensable in
selecting patients who would benefit from primary or ear-
ly cystectomy.
However, if no BCG is available, patients who would not
be classified as the highest risk category may still be consid-
ered for upfront radical cystectomy as the safest option from
the oncological point of view (Table 1, option 6). Long-term
oncological outcomes of cystectomy for those patients show
disease-specific survival of 80–90 % [51].
Conclusions
High-risk NMIBC represents a challenging cohort of patients
where the risk of recurrence and progression has to be bal-
anced against treatment morbidity. Intravesical BCG has been
first line treatment for many of those patients but there is a
current worldwide shortage.
In this climate, judicious use of limited BCG supply should
be made. Therapeutic choices in this patient group are listed in
Table 1. For patients in the high-risk group without CIS, main-
tenance BCG can be stopped after 1 year. For those with CIS,
a reduced dose of BCG for years 2 and 3 could be considered.
An alternative strategy for patients at lower risk of progres-
sion (pTaG3) would include an induction course of mitomycin
C that should be followed by maintenance as level 1 evidence
suggests a response rate even in the high-risk group associated
with MMC.
Thermotherapy or EMDA with mitomycin have both
shown good response rates but the studies have been limited
with short follow-up data. Recruitment of patients in clinical
trials would be helpful.
In patients fit for surgical intervention, as strong case can
be made for radical cystectomy and patients need to be
counselled about this prior to embarking upon intravesical
therapies.
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